Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
KinaSense
company
About
KinaSense's technology measures the effects of cancer drugs that inhibit growth signals from a kinase.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $200K
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2013
- Number Of Employee
- 1 - 10
- Operating Status
- Close
Tyrosine kinase inhibitors (TKIs) are used to treat a variety of cancer types. The current diagnostic tools lack the predictive power to match the right patient with the right TKI. KinaSense is developing technologies that can be used to predict whether a given patient will benefit from a specific TKI.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$200K
KinaSense has raised a total of
$200K
in funding over 2 rounds. Their latest funding was raised on
Mar 14, 2016 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 14, 2016 | Grant | $200K | 1 |
National Institutes of Health
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
KinaSense is funded by 1 investors.
National Institutes of Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
